🇺🇸 BRIGATINIB in United States

1,931 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Death — 353 reports (18.28%)
  2. Non-Small Cell Lung Cancer — 246 reports (12.74%)
  3. Off Label Use — 205 reports (10.62%)
  4. Product Dose Omission Issue — 180 reports (9.32%)
  5. Fatigue — 175 reports (9.06%)
  6. Diarrhoea — 174 reports (9.01%)
  7. Nausea — 164 reports (8.49%)
  8. Neoplasm Progression — 157 reports (8.13%)
  9. Metastases To Central Nervous System — 144 reports (7.46%)
  10. Drug Ineffective — 133 reports (6.89%)

Source database →

BRIGATINIB in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is BRIGATINIB approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for BRIGATINIB in United States?

Marketing authorisation holder not available in our data.